Novo Nordisk (NOVOB DC) and Hims & Hers (HIMS) are expected to announce a new partnership on Monday for Novo to sell its weight-loss drug on the Hims platform, Bloomberg reports citing sources
Newsquawk Staff ·
Novo Nordisk (NOVOB DC) and Hims & Hers (HIMS) are expected to announce a new partnership on Monday for Novo to sell its weight-loss drug on the Hims platform, Bloomberg reports citing sources.
What it means
The anticipated partnership between Novo Nordisk and Hims & Hers represents a strategic move for both companies, leveraging Hims' digital platform to enhance the distribution of Novo's weight-loss drug. This collaboration could signify a growing trend in the pharmaceutical sector towards digital health partnerships, potentially affecting competitors and opening new revenue streams for both parties involved.
Sources
- Genmab (GMAB/GMAB DC) announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab
- UK PM Burnham declines to rule out another Brexit referendum at PMQs
- Announcement UK Chancellor Healey will freeze NHS prescription charges at GBP 9.90 for another year may have been removed from the budget in a late night scramble, reports The Telegraph
- Eli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trial
- Novo Nordisk (NOVOB DC) says investigational cagrisema 2.4 mg/2.4 mg showed 25% average weight loss in women in redefine 1 post hoc analysis
Related headlines
- TPG pursues USD 5bln acquisition of UK data centre group Ark, according to FT9 hours ago
- Syngenta targets at least a USD 66bln valuation in Hong Kong IPO11 hours ago
- HP (HPQ), Asus (2357 TT) and Acer (2353 TT) are shifting some PC production from Thailand and Vietnam back to China to combat soaring component costs driven by AI-related memory and storage shortages, reports Nikkei citing sources19 hours ago
- Universal Music Group (UMG NA) discusses going private with buyout firms, according to Bloomberg1 day ago
- Japan's Sakana AI to build homegrown model to cut US and China reliance, reports Nikkei1 day ago
- Japan's Sakana AI to build homegrown model to cut US and China reliance, Nikkei reports1 day ago
- Foxconn (2317 TT) has brought online an AI factory powered by an NVIDIA (NVDA) DGX supercomputing cluster2 days ago
- UK PM Burnham rules out an early election; says, "I don’t think people want another backward looking squabble. They want me to get on with the job", The Times reports2 days ago
- US FDA has approved Novo's (NOVOB DC) once-weekly insulin treatment for paediatric patients with type 2 diabetes mellitus4 days ago
- Meta's (META) Muse AI to counter China models with subscribers, not ads, Nikkei reports4 days ago
- Toyota (TM) to recall 68k late model 2022-2024 Lexus NX vehicles in the US due to a display flaw4 days ago
- Genmab (GMAB) Phase 3 Rina data in ovarian cancer shows PFS and OS endpoints were met4 days ago
- TikTok’s US entity is reportedly exploring deals to secure multiple gigawatts of computing capacity over the coming years, according to CNBC4 days ago
- Infosys (INFY) Q2 2026 (INR): Net profit 78.2bln (exp. 79.3bln ), revenue 492.4bln (exp. 491.3bln); lowers FY27 revenue view5 days ago
- Anthropic and Hg have agreed to form an independent consultancy Co. targeting corporate clients, FT reports citing sources5 days ago